Patient-reported outcomes in real-world use of benralizumab in patients with severe eosinophilic asthma in Belgium - BE-REAL

Study identifier:D3250R00059

ClinicalTrials.gov identifier:NCT04221802

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A multicentre single arm observational prospective study to assess demographic characteristics burden of disease PRO’s in uncontrolled, severe eosinophilic asthma patients aged 18y or older and qualifying for treatment with benralizumab in BE

Medical condition

Severe Asthma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

76

Study type

Observational

Age

18 Years - 99 Years

Date

Study Start Date: 23 Dec 2019
Primary Completion Date: 13 May 2024
Study Completion Date: 13 May 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria